Topoisomerase levels determine chemotherapy response in vitro and in vivo

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 26, 2008, Pages 9053-9058

  Burgess, Darren J ^a   Doles, Jason ^c   Zender, Lars ^a   Xue, Wen ^a   Ma, Beicong ^a,b   McCombie, W Richard ^a   Hannon, Gregory J ^a,b   Lowe, Scott W ^a,b   Hemann, Michael T ^a,c  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Chk2; Doxorubicin; RNAi screen; Top1; Top2A

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; IRINOTECAN; MAFOSFAMIDE; SHORT HAIRPIN RNA; TOPOTECAN; DNA BINDING PROTEIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE II ALPHA; SMALL INTERFERING RNA; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; TREATMENT RESPONSE; ANIMAL; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; METABOLISM; NEOPLASM; RECURRENT DISEASE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; MICE; NEOPLASMS; RECURRENCE; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 47949130625     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0803513105     Document Type: Article

References (42)

1. Gros P, Ben Neriah YB, Croop JM, Housman DE (1986) Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323:728-731.
2. Mao Y, et al. (1999) Mutations of human topoisomerase IIα affecting multidrug resistance and sensitivity. Biochemistry 38:10793-10800.
3. Shah NP, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125.
4. Lowe SW, Ruley HE, Jacks T, Housman DE (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967.
5. Hannon GJ (2002) RNA interference. Nature 418:244-251.
6. Farmer H, et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921.
7. Brummelkamp TR, et al. (2006) An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2:202-206.
8. Berns K, et al. (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402.
9. Whitehurst AW, et al. (2007) Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446:815-819.
10. Iorns E, Lord CJ, Turner N, Ashworth A (2007) Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 6:556-568.
11. Fortune JM, Osheroff N (2000) Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 64:221-253.
12. Schmitt CA, et al. (2002) Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1:289-298.
13. Dickins RA, et al. (2005) Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 37:1289-1295.
14. Hemann MT, et al. (2004) Suppression of tumorigenesis by the p53 target PUMA. Proc Natl Acad Sci USA 101:9333-9338.
15. Hemann MT, et al. (2003) An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet 33:396-400.
16. Silva JM, et al. (2005) Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet 37:1281-1288.
17. Witt AE, et al. (2006) Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer. J Proteome Res 5:599-610.
18. Schmitt CA, et al. (2002) A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109:335-346.
19. Sherr CJ (2001) The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2:731-737.
20. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW (1999) INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13:2670-2677.
21. Yu Q, Rose JH, Zhang H, Pommier Y (2001) Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. FEBS Lett 505:7-12.
22. Mukhopadhyay UK, Senderowicz AM, Ferbeyre G (2005) RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells. Cancer Res 65:2872-2881.
23. Hirao A, et al. (2002) Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol 22:6521-6532.
24. Akimitsu N, et al. (2003) Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase IIalpha. Genes Cells 8:393-402.
25. Wang JC (2002) Cellular roles of DNA topoisomerases: A molecular perspective Nat Rev Mol Cell Biol 3:430-440.
26. Gudkov AV, et al. (1993) Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci USA 90:3231-3235.
27. Strasser A, Harris AW, Jacks T, Cory S (1994) DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79:329-339.
28. Hsiang YH, Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726.
29. Hsiang YH, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878.
30. Nitiss J, Wang JC (1988) DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci USA 85:7501-7505.
31. Morham SG, Kluckman KD, Voulomanos N, Smithies O (1996) Targeted disruption of the mouse topoisomerase I gene by camptothecin selection. Mol Cell Biol 16:6804-6809.
32. Miao ZH, et al. (2006) 4-nitroquinoline-1-oxide induces the formation of cellular topoisomerase I-DNA cleavage complexes. Cancer Res 66:6540-6545.
33. Trigueros S, Roca J (2002) Failure to relax negative supercoiling of DNA is a primary cause of mitotic hyper-recombination in topoisomerase-deficient yeast cells. J Biol Chem 277:37207-37211.
34. Uemura T, Yanagida M (1984) Isolation of type I and II DNA topoisomerase mutants from fission yeast: Single and double mutants show different phenotypes in cell growth and chromatin organization. EMBO J 3:1737-1744.
35. Rottenberg S, et al. (2007) Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA 104:12117-12122.
36. Schmitt CA, Rosenthal CT, Lowe SW (2000) Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 6:1029-1035.
37. Mano MS, Rosa DD, de Azambuja E, Ismael GF, Durbecq V (2007) The 17q12-q21 amplicon: Her2 and topoisomerase-IIα and their importance to the biology of solid tumours. Cancer Treat Rev 33:64-77.
38. Tanner M, et al. (2006) Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 24:2428-2436.
39. Jarvinen TA, Liu ET (2003) Topoisomerase IIα gene (TOP2A) amplification and deletion in cancer: More common than anticipated. Cytopathology 14:309-313.
40. Boonsong A, et al. (2000) Characterization of the topoisomerase I locus in human colorectal cancer. Cancer Genet Cytogenet 121:56-60.
41. Brezinova J, et al. (2005) Prognostic significance of del(20q) in patients with hematological malignancies. Cancer Genet Cytogenet 160:188-192.
42. Huesken D, et al. (2005) Design of a genome-wide siRNA library using an artificial neural network. Nat Biotechnol 23:995-1001.